CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
University of Campania Luigi Vanvitelli
University of Turin, Italy
Sun Yat-sen University
National Cancer Institute, Naples
Ludwig-Maximilians - University of Munich
National Cancer Institute, Naples
Sun Yat-sen University
First Affiliated Hospital of Zhejiang University
Shanghai Henlius Biotech
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Second Affiliated Hospital, School of Medicine, Zhejiang University
Fujian Cancer Hospital
Shanghai Zhongshan Hospital
Liaoning Cancer Hospital & Institute
Shanghai Celfuture Biotech Co., Ltd.
NSABP Foundation Inc
Yonsei University
Jiangsu Cancer Institute & Hospital
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Shanghai Changzheng Hospital
Fudan University
Fudan University
Benaroya Research Institute
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sichuan Cancer Hospital and Research Institute
Korea Cancer Center Hospital
Technische Universität Dresden
Gruppo Oncologico del Nord-Ovest
Karolinska University Hospital
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Peking University
Shanghai Jiao Tong University School of Medicine
Gruppo Oncologico del Nord-Ovest
Peking University
Huazhong University of Science and Technology
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Shanghai Zhongshan Hospital
Japan Clinical Cancer Research Organization
National University Hospital, Singapore
Association pour la Recherche sur le Temps Biologique et la Chronothérapie
National Cancer Institute (NCI)
Karolinska University Hospital
Fudan University
Institute of Oncology Ljubljana
Institute of Oncology Ljubljana
Enzon Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Fudan University
University of Virginia
Theagenio Cancer Hospital